X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frazier Life Sciences
Deal Size: $52.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 03, 2024
Details:
The financing will focus on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications by using company's platform technology which uses small molecule targeting to deliver radioisotopes to a broad range of cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: GordonMD Global Investments
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
